Skip to Content

Ataxia-Telangiectasia

By

James Fernandez

, MD, PhD, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

Last full review/revision Apr 2021| Content last modified Apr 2021

Ataxia-telangiectasia results from a DNA repair defect that frequently results in humoral and cellular deficiency; it causes progressive cerebellar ataxia, oculocutaneous telangiectasias, and recurrent sinopulmonary infections. IgA and serum alpha-1 fetoprotein levels are measured. Genetic testing is needed to confirm the diagnosis. Treatment is with prophylactic antibiotics or with immune globulin.

(See also Overview of Immunodeficiency Disorders and Approach to the Patient With an Immunodeficiency Disorder.)

Ataxia-telangiectasia is an autosomal-recessive primary immunodeficiency disorder that involves combined humoral and cellular deficiencies. Estimated incidence is 1 in 20,000 to 100,000 births. Ataxia-telangiectasia is caused by mutations in the gene that encodes ataxia-telangiectasia–mutated (ATM) protein. ATM is involved in detection of DNA damage and helps control the rate of cell growth and division.

Patients often lack IgA and IgE and have a progressive T-cell defect.

Symptoms and Signs of Ataxia-Telangiectasia

Age at onset of neurologic symptoms and evidence of immunodeficiency vary.

Ataxia is frequently the first symptom and usually develops when children begin to walk. Progression of neurologic symptoms leads to severe disability. Speech becomes slurred, choreoathetoid movements and nystagmus develop, and muscle weakness usually progresses to muscle atrophy.

Telangiectasias may not appear until age 4 to 6 years; they are most prominent on the bulbar conjunctivae, ears, antecubital and popliteal fossae, and sides of the neck.

Recurrent sinopulmonary infections lead to recurrent pneumonia, bronchiectasis, and chronic restrictive pulmonary disease.

Certain endocrine abnormalities (eg, gonadal dysgenesis, testicular atrophy, diabetes mellitus) may occur.

Frequency of cancer (especially leukemia, lymphoma, brain tumors, and gastric cancer) is high. Cancer typically occurs after age 10 and at a rate of about 1%/year but is a lifelong risk and can occur at any age.

Diagnosis of Ataxia-Telangiectasia

  • IgA and serum alpha-1 fetoprotein levels
  • Genetic testing

The following clinical findings suggest the diagnosis of ataxia-telangiectasia:

  • Cerebellar ataxia (particularly when telangiectasias are present)
  • Low levels of IgA (present in 80% of patients with this disorder)
  • High levels of serum alpha-1 fetoprotein

If karyotype analysis is done, chromosome breaks, consistent with a defect in DNA repair, are often seen.

Diagnosis of ataxia-telangiectasia is confirmed by identifying mutations on both alleles of the gene for ATM protein. Because carriers of an ataxia-telangiectasia mutation usually remain asymptomatic, testing siblings for a carrier state can help predict their chance of having an affected child.

Testing for endocrine abnormalities and cancers is done based on clinical presentation.

Treatment of Ataxia-Telangiectasia

  • Supportive care using prophylactic antibiotics or immune globulin (IgG) replacement therapy

Treatment with prophylactic antibiotics or immune globulin may help patients with ataxia-telangiectasia.

In one small study, treatment with amantadine resulted in minimal improvement in motor function, but there is no effective treatment for the progressive neurologic deterioration, which causes death, usually by age 30.

Chemotherapy is often indicated for treatment of associated cancers.

Key Points

  • Ataxia-telangiectasia involves combined humoral and cellular deficiencies.
  • Ataxia is frequently the first symptom and usually develops when children begin to walk.
  • There is no effective treatment for the progressive neurologic deterioration.

Drugs Mentioned In This Article

Drug Name Select Trade
immune globulin Gammagard S/D
amantadine No US brand name

Copyright © 2021 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer